Dendritic Cell Therapy

Denvax Publication On Dendritic Cell Therapy

Dendritic Cell Therapy

Hepatocellular carcinoma responds to dendritic cell therapy - case study on 14 patients treated from year 2005-2008

Jamal A. Khan and Sharmin Yaqin

Dendritic cells (dc) are the master immune cells eliciting both arms of immunity. cells are almost totally dependent on dc for their maturation. Naive t cells are transformed into committed t lymphocytes with the brief exposure of dc, and during this interaction the specific epitopic representation is guaranteed to pass to t cells. Hepatocellular carcinoma (HCC) is fairly resistant cancer not responding to chemotherapy or mabs. Life span and quality of life get hampered. We have treated 14 patients of HCC from the year 2005 to 2008. 7 patients responded to therapy with decrease of alfafetoprotein to half. These patients have survived on an average of 23 months with 2 patients living for 36 months. Dendritic cell therapy seems to be good option for HCC patients and a large trial is warranted.

Presented in 'Cancer Immunology and Immunotherapy: Building on Success' conference held in National Institute of Health, Bethesda, MD, USA on September 22-23, 2011.

Get in Touch

Connect any of our offices to begin your Denvax Treatment

contact us